High COVID-19 virus replication rates, the creation of antigen-antibody immune complexes and indirect haemagglutination resulting in thrombosis.
作者信息
Roe Kevin
机构信息
San Jose, CA, USA.
出版信息
Transbound Emerg Dis. 2020 Jul;67(4):1418-1421. doi: 10.1111/tbed.13634. Epub 2020 Jun 3.
Abstract
摘要
相似文献
1
High COVID-19 virus replication rates, the creation of antigen-antibody immune complexes and indirect haemagglutination resulting in thrombosis.新冠病毒的高复制率、抗原-抗体免疫复合物的形成以及间接血凝导致血栓形成。
Transbound Emerg Dis. 2020 Jul;67(4):1418-1421. doi: 10.1111/tbed.13634. Epub 2020 Jun 3.
2
Infectious salmon anaemia virus replication and induction of alpha interferon in Atlantic salmon erythrocytes.传染性鲑鱼贫血病毒在大西洋鲑鱼红细胞中的复制及α干扰素的诱导。
Virol J. 2008 Feb 28;5:36. doi: 10.1186/1743-422X-5-36.
3
The use of monoclonal antibodies in (reverse) passive haemagglutination tests for herpes simplex virus antigens and antibodies.单克隆抗体在用于单纯疱疹病毒抗原和抗体的（反向）被动血凝试验中的应用。
J Med Virol. 1983;11(4):295-306. doi: 10.1002/jmv.1890110405.
4
5
A simplified objective method for quantification of peste des petits ruminants virus or neutralizing antibody.一种用于小反刍兽疫病毒或中和抗体定量的简化客观方法。
J Virol Methods. 2000 Sep;89(1-2):89-95. doi: 10.1016/s0166-0934(00)00206-8.
6
A novel rapid direct haemagglutination-inhibition assay for measurements of humoral immune response against non-haemagglutinating strains in vaccinated chickens.一种用于测量接种疫苗鸡针对非血凝性毒株的体液免疫反应的新型快速直接血凝抑制试验。
Heliyon. 2017 Oct 31;3(10):e00428. doi: 10.1016/j.heliyon.2017.e00428. eCollection 2017 Oct.
7
Comparison of passive haemagglutination and haemagglutination-inhibition techniques for detection of antibodies to rubella virus.用于检测风疹病毒抗体的被动血凝和血凝抑制技术的比较。
J Clin Pathol. 1979 Feb;32(2):128-31. doi: 10.1136/jcp.32.2.128.
8
Antigenic relationships of lymphocytic choriomeningitis virus and Tacaribe virus in the indirect haemagglutination test.淋巴细胞性脉络丛脑膜炎病毒与塔卡里伯病毒在间接血凝试验中的抗原关系
Bull World Health Organ. 1975;52(4-6):437-9.
9
The pathogenesis of Aleutian disease of mink. I. In vivo viral replication and the host antibody response to viral antigen.水貂阿留申病的发病机制。I. 体内病毒复制及宿主对病毒抗原的抗体反应。
J Exp Med. 1969 Sep 1;130(3):575-93. doi: 10.1084/jem.130.3.575.
10
Protection of mice from lethal influenza: evidence that defective interfering virus modulates the immune response and not virus multiplication.保护小鼠免受致命性流感：有证据表明缺陷干扰病毒可调节免疫反应而非病毒增殖。
J Gen Virol. 1986 May;67 ( Pt 5):839-50. doi: 10.1099/0022-1317-67-5-839.
引用本文的文献
1
A Comprehensive In Silico Study of New Metabolites from with SARS-CoV-2 Inhibitory Activity.基于 SARS-CoV-2 抑制活性的 新型代谢产物的全面计算机研究。
Molecules. 2022 Oct 29;27(21):7369. doi: 10.3390/molecules27217369.
2
Circulating multimeric immune complexes contribute to immunopathology in COVID-19.循环的多聚体免疫复合物有助于 COVID-19 的免疫病理学。
Nat Commun. 2022 Sep 26;13(1):5654. doi: 10.1038/s41467-022-32867-z.
3
A Deadly Embrace: Hemagglutination Mediated by SARS-CoV-2 Spike Protein at Its 22 N-Glycosylation Sites, Red Blood Cell Surface Sialoglycoproteins, and Antibody.致命的拥抱：SARS-CoV-2 刺突蛋白 22 个 N-糖基化位点、红细胞表面唾液糖蛋白和抗体介导的血凝
Int J Mol Sci. 2022 Feb 25;23(5):2558. doi: 10.3390/ijms23052558.
4
Prevalence of Symptoms in Patients Discharged from COVID Care Facility of NIMS Hospital: Is RT PCR Negativity Truly Reflecting Recovery? A Single-Centre Observational Study.尼姆斯医院新冠护理设施出院患者的症状患病率：逆转录聚合酶链反应阴性是否真的反映康复？一项单中心观察性研究。
Int J Gen Med. 2021 Mar 25;14:1069-1078. doi: 10.2147/IJGM.S295499. eCollection 2021.
5
A viral infection explanation for Kawasaki disease in general and for COVID-19 virus-related Kawasaki disease symptoms.川崎病的病毒感染解释，一般来说，也是与 COVID-19 病毒相关的川崎病症状的解释。
Inflammopharmacology. 2020 Oct;28(5):1219-1222. doi: 10.1007/s10787-020-00739-x. Epub 2020 Jul 7.
6
SARS-CoV-2, where to now?严重急性呼吸综合征冠状病毒2，现在何去何从？
Transbound Emerg Dis. 2020 Jul;67(4):1411-1413. doi: 10.1111/tbed.13654. Epub 2020 Jun 19.
本文引用的文献
1
Explanation for COVID-19 infection neurological damage and reactivations.新型冠状病毒肺炎感染导致神经损伤及再激活的解释。
Transbound Emerg Dis. 2020 Jul;67(4):1414-1415. doi: 10.1111/tbed.13594. Epub 2020 May 4.
2
COVID-19 and Thrombotic or Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and Follow-Up: JACC State-of-the-Art Review.新型冠状病毒肺炎与血栓栓塞性疾病：预防、抗栓治疗与随访的相关问题：美国心脏病学会临床实践更新。
J Am Coll Cardiol. 2020 Jun 16;75(23):2950-2973. doi: 10.1016/j.jacc.2020.04.031. Epub 2020 Apr 17.
3
Thromboembolic risk and anticoagulant therapy in COVID-19 patients: emerging evidence and call for action.新型冠状病毒肺炎患者的血栓栓塞风险和抗凝治疗：新出现的证据和行动呼吁。
Br J Haematol. 2020 Jun;189(5):846-847. doi: 10.1111/bjh.16727. Epub 2020 May 4.
4
Neurologic Manifestations of Hospitalized Patients With Coronavirus Disease 2019 in Wuhan, China.中国武汉住院的 2019 年冠状病毒病患者的神经系统表现。
JAMA Neurol. 2020 Jun 1;77(6):683-690. doi: 10.1001/jamaneurol.2020.1127.
5
Coagulopathy and Antiphospholipid Antibodies in Patients with Covid-19.新型冠状病毒肺炎患者的凝血障碍与抗磷脂抗体
N Engl J Med. 2020 Apr 23;382(17):e38. doi: 10.1056/NEJMc2007575. Epub 2020 Apr 8.
6
Structural and molecular modelling studies reveal a new mechanism of action of chloroquine and hydroxychloroquine against SARS-CoV-2 infection.结构和分子建模研究揭示了氯喹和羟氯喹抗 SARS-CoV-2 感染的新作用机制。
Int J Antimicrob Agents. 2020 May;55(5):105960. doi: 10.1016/j.ijantimicag.2020.105960. Epub 2020 Apr 3.
7
The use of anti-inflammatory drugs in the treatment of people with severe coronavirus disease 2019 (COVID-19): The Perspectives of clinical immunologists from China.抗炎药物在治疗重症新型冠状病毒病 2019（COVID-19）患者中的应用：来自中国临床免疫学家的观点。
Clin Immunol. 2020 May;214:108393. doi: 10.1016/j.clim.2020.108393. Epub 2020 Mar 25.
8
Clinical characteristics of severe acute respiratory syndrome coronavirus 2 reactivation.严重急性呼吸综合征冠状病毒 2 再激活的临床特征。
J Infect. 2020 May;80(5):e14-e17. doi: 10.1016/j.jinf.2020.03.001. Epub 2020 Mar 20.
9
Accelerated viral dynamics in bat cell lines, with implications for zoonotic emergence.蝙蝠细胞系中的病毒动力学加速，对人畜共患病的出现有影响。
Elife. 2020 Feb 3;9:e48401. doi: 10.7554/eLife.48401.
10
Development of Universal Influenza Vaccines Targeting Conserved Viral Proteins.针对保守病毒蛋白的通用流感疫苗的研发。
Vaccines (Basel). 2019 Nov 1;7(4):169. doi: 10.3390/vaccines7040169.
Zotero 插件